Fig. 5.
Electrophoretic mobility shift assay to assess nuclear factor (NF)-κB (Fig. 5a, Supershift) and p53 (Fig. 5b) DNA binding activity. Nuclear extracts of hepatic stellate cells (HSCs) at days 2 and 7 in control and in atorvastatin 10−7 mol/L were assessed using a NF-κB and p53 binding site as probe. Please note that in both quiescent and activated HSC, there are no differences between the control and the cells treated with atorvastatin. We could confirm the data in five different blots of five independent experiments.